News & Analysis as of

Joint Venture Celltrion

Goodwin

TRUXIMA launches as first U.S. Rituxan® biosimilar approved for RA

Goodwin on

Teva and Celltrion Healthcare announced today the U.S. launch of TRUXIMA® (rituximab-abbs) for rheumatoid arthritis (RA). TRUXIMA®, which originally launched in November 2019, is now approved to treat RA, non-Hodgkin lymphoma...more

Goodwin

Celltrion Reportedly Partnering with George Steuart Health on Sri Lankan Remsima (infliximab)

Goodwin on

Lanka Business News is reporting that Celltrion and George Steuart Health have teamed up to launch Remsima (infliximab) in Sri Lanka...more

2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide